

Yeda Research and Development — Weizmann Institute's Technology-Transfer Company (Rehovot)

City Innovation Library · Good practice · Israel

Quality score: 71/100

Evidence strength: Strong

Summary

Since 1959, the Weizmann Institute's wholly owned commercialisation arm has turned basic research into drugs like Copaxone and Erbitux, earning the Institute \$50–100m a year in royalties by 2013 and driving \$23bn in global sales by 2022.

Key dimensions

Dimension	Score
Evidence of impact / measured results	3/3
Transferability / demonstrated replication	2/3
Scalability	3/3
Sustainability / continuity	3/3
Innovation	2/3
Inclusiveness / equity	1/3
Multi-stakeholder collaboration	1/3

Evaluated by C-NAPSE

Data sources

[C-NAPSE web research](#) — accessed 2026-07-14

[Yeda Research and Development Company Ltd. \(wholly owned by the Weizmann Institute of Science\)](#) — accessed 2026-07-14

[Yeda Research and Development](#) — official site — accessed 2026-07-14

[Wikipedia](#) — Weizmann Institute of Science — accessed 2026-07-14

[IsraelValley](#) — Weizmann Institute's Innovation and Technology Transfer Office — accessed 2026-07-14

[The Olam](#) — Weizmann and the Yeda Model — accessed 2026-07-14

Cite this — Evidoria. *Yeda Research and Development — Weizmann Institute's Technology-Transfer Company (Rehovot)*. Persistent ID: c75ee1d9-67f8-4661-996d-1eebd3dfe5b8.